HU201906B
(en)
*
|
1987-03-04 |
1991-01-28 |
Sandoz Ag |
Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
|
EP0755685A4
(fr)
*
|
1994-04-15 |
2000-05-03 |
Meiji Seika Kaisha |
Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition
|
HU226526B1
(en)
*
|
1996-12-18 |
2009-03-30 |
Teva Pharma |
Phenylethylamine derivatives, use of them for preparation of pharmaceutical compositions and the pharmaceutical compositions comprising them
|
US6251938B1
(en)
|
1996-12-18 |
2001-06-26 |
Teva Pharmaceutical Industries, Ltd., |
Phenylethylamine derivatives
|
CA2275425C
(fr)
|
1996-12-18 |
2009-08-04 |
Michael Chorev |
Derives d'aminoindan
|
US6316023B1
(en)
*
|
1998-01-12 |
2001-11-13 |
Novartis Ag |
TTS containing an antioxidant
|
GB9800526D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Ciba Geigy Ag |
Organic compounds
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
CN1406126A
(zh)
|
1998-10-01 |
2003-03-26 |
诺瓦提斯公司 |
新型缓释口服制剂
|
US20040209849A1
(en)
*
|
1998-11-27 |
2004-10-21 |
Sanochemia Pharmazeutika Aktiengesellschaft |
Use of effectors of the central cholinergic nervous system for treatment of delirium
|
ATE306264T1
(de)
*
|
1998-12-11 |
2005-10-15 |
Bonnie M Davis |
Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
US6534541B1
(en)
|
1999-10-19 |
2003-03-18 |
Novartis Ag |
Treatment of ocular disorders
|
CA2406383A1
(fr)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
Agents de reduction de a.beta.42
|
US20040010038A1
(en)
*
|
2002-02-27 |
2004-01-15 |
Eran Blaugrund |
Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
|
CZ20023555A3
(cs)
|
2002-10-24 |
2004-01-14 |
Léčiva, A.S. |
Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
|
GEP20094759B
(en)
*
|
2002-10-24 |
2009-08-25 |
Merz Pharma Gmbh & Co Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
EP1603548A4
(fr)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
Composition et methode de traitement de troubles neurodegeneratifs
|
US7521481B2
(en)
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
CN1898201A
(zh)
*
|
2003-10-21 |
2007-01-17 |
森蒂有限公司 |
可抑制胆碱酯酶和释放药理学活性试剂的氨基甲酸酯
|
GB2409453A
(en)
|
2003-12-24 |
2005-06-29 |
Generics |
Process for the preparation of aminoalkyl phenylcarbamates
|
WO2006001877A2
(fr)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
|
CN1946906A
(zh)
*
|
2004-04-29 |
2007-04-11 |
吉斯通护岸系统股份有限公司 |
用于墙、护墙和类似物的饰面
|
WO2006004201A1
(fr)
*
|
2004-07-01 |
2006-01-12 |
Eisai R & D Management Co., Ltd. |
Promoteur de la régénérescence nerveuse
|
WO2006020852A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
|
WO2006020850A2
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
|
CA2618985A1
(fr)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
|
JP4954886B2
(ja)
*
|
2004-11-08 |
2012-06-20 |
エムキュア ファーマシューティカルズ リミテッド |
(s)−3−[(1−ジメチルアミノ)エチル]−フェニル−n−エチル−n−メチル−カルバミン酸の効率的製造方法
|
GB0507298D0
(en)
|
2005-04-11 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
CA2615063A1
(fr)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
Formes posologiques et preparations a charge medicamenteuse elevee
|
ES2267399B1
(es)
|
2005-08-04 |
2008-02-01 |
Ragactives, S.L. |
Procedimiento para la obtencion de carbamatos de fenilo.
|
ATE546202T1
(de)
|
2005-09-15 |
2012-03-15 |
Sony Computer Entertainment Inc |
Kabelloser videospielcontroller und verfahren zum betreiben des kabellosen videospielcontrollers
|
TWI389709B
(zh)
*
|
2005-12-01 |
2013-03-21 |
Novartis Ag |
經皮治療系統
|
CA2634166C
(fr)
*
|
2005-12-09 |
2016-03-29 |
Marta Weinstock-Rosin |
Utilisation de ladostigil a faible dose pour la neuroprotection
|
TW200744576A
(en)
*
|
2006-02-24 |
2007-12-16 |
Teva Pharma |
Propargylated aminoindans, processes for preparation, and uses thereof
|
US7767843B2
(en)
*
|
2006-03-02 |
2010-08-03 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
EP2046119A2
(fr)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Traitement de troubles psychiatriques
|
EP2054373B1
(fr)
*
|
2006-08-17 |
2010-06-30 |
Alembic Limited |
Procédé pour la préparation de rivastigmine amélioré
|
WO2008037433A1
(fr)
|
2006-09-29 |
2008-04-03 |
Synthon B.V. |
Procédé de fabrication de carbamates d'aminoalkylphényle et intermédiaires de cette fabrication
|
KR20090087009A
(ko)
|
2006-10-27 |
2009-08-14 |
메디베이션 뉴롤로지 인코퍼레이티드 |
아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
|
EP1942100A1
(fr)
*
|
2007-01-04 |
2008-07-09 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Formes amorphes et cristallines dýhydrogénotartrate de rivastigmine
|
JP2010518010A
(ja)
*
|
2007-02-02 |
2010-05-27 |
コルシド・ファーマシューティカルズ・インコーポレイテッド |
コリンエステラーゼを阻害する化合物
|
US8013181B2
(en)
*
|
2007-04-10 |
2011-09-06 |
Dr. Reddy's Laboratories Limited |
Preparation of rivastigmine and its salts
|
CN101707952B
(zh)
*
|
2007-04-16 |
2012-08-29 |
上海特化医药科技有限公司 |
一种制备利伐斯的明的方法及其中间体
|
US7884121B2
(en)
*
|
2007-06-11 |
2011-02-08 |
Apotex Pharmachem Inc. |
Process for the preparation of phenylcarbamates
|
US20090048229A1
(en)
*
|
2007-07-18 |
2009-02-19 |
Rupniak Nadia M J |
Methods for promoting wakefulness
|
US8593728B2
(en)
*
|
2009-02-19 |
2013-11-26 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Multilayer photonic structures
|
US20090082436A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched rivastigmine
|
CN101910110B
(zh)
*
|
2008-01-10 |
2013-05-22 |
上海医药工业研究院 |
利凡斯的明的制备方法、其中间体以及中间体的制备方法
|
US8420846B2
(en)
|
2008-08-25 |
2013-04-16 |
Jubilant Life Sciences Limited |
Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
|
US20100087768A1
(en)
*
|
2008-10-02 |
2010-04-08 |
Forlano Paula |
Transdermal drug delivery system for liquid active ingredient
|
GB0823554D0
(en)
*
|
2008-12-24 |
2009-01-28 |
Novartis Ag |
Process for the preparation of optically active compounds using transfer hydrogenation
|
CN101823970B
(zh)
*
|
2009-03-03 |
2013-05-08 |
江苏恩华药业股份有限公司 |
卡巴拉汀及其中间体的合成方法
|
DK2515886T3
(en)
|
2009-12-22 |
2018-06-14 |
Luye Pharma Ag |
Transdermal therapeutic system for administration of rivastigmine or derivatives thereof
|
US10076502B2
(en)
|
2009-12-22 |
2018-09-18 |
Luye Pharma Ag |
Transdermal therapeutic system for administering rivastigmine or derivatives thereof
|
ES2363395B1
(es)
*
|
2010-01-20 |
2012-02-23 |
Farmalider, S.A. |
Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
|
BR112012019923A2
(pt)
|
2010-02-09 |
2016-08-09 |
Univ Johns Hopkins |
métodos e composições para melhorar a função cognitiva
|
US20130011431A1
(en)
|
2010-03-29 |
2013-01-10 |
Novartis Ag |
Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant
|
WO2011151669A1
(fr)
|
2010-06-02 |
2011-12-08 |
Jubilant Life Sciences Limited |
Procédé de production d'un isomère énantiomériquement enrichi d'un dérivé du 3-(1-aminoéthyle) phényle et son utilisation pour produire de la rivastigmine ou son sel pharmaceutiquement acceptable
|
WO2011151359A1
(fr)
|
2010-06-02 |
2011-12-08 |
Noscira, S.A. |
Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
|
US8852900B2
(en)
|
2010-06-17 |
2014-10-07 |
Codexis, Inc. |
Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol
|
EP2640391B1
(fr)
|
2010-11-15 |
2015-11-11 |
Agenebio, Inc. |
Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
|
EP2468274B1
(fr)
|
2010-12-14 |
2015-07-01 |
Acino AG |
Système thérapeutique transdermique pour l'enrichissement d'une substance active
|
CN102786441B
(zh)
*
|
2011-05-18 |
2013-11-13 |
浙江海正药业股份有限公司 |
利凡斯的明的制备方法、其中间体以及中间体的制备方法
|
US9585862B2
(en)
|
2011-05-20 |
2017-03-07 |
Sk Chemicals Co., Ltd. |
Patch containing rivastigmine
|
AR082640A1
(es)
*
|
2011-08-25 |
2012-12-19 |
Amarin Technologies S A |
Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
|
WO2013031992A1
(fr)
|
2011-08-31 |
2013-03-07 |
積水メディカル株式会社 |
Timbre transdermique
|
CN103073456B
(zh)
*
|
2011-10-26 |
2014-03-19 |
连云港润众制药有限公司 |
重酒石酸卡巴拉汀中间体的制备方法
|
EP2594261A1
(fr)
|
2011-11-18 |
2013-05-22 |
Labtec GmbH |
Composition pour administration transdermique de rivastigmine
|
WO2013142339A1
(fr)
|
2012-03-23 |
2013-09-26 |
Novartis Ag |
Système thérapeutique transdermique et procédé associé
|
ES2449215B1
(es)
*
|
2012-09-17 |
2014-07-14 |
Galenicum Health S.L. |
Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
|
KR20140038237A
(ko)
|
2012-09-20 |
2014-03-28 |
에스케이케미칼주식회사 |
리바스티그민의 안정성이 개선된 의약품
|
CA2891122C
(fr)
|
2012-11-14 |
2021-07-20 |
The Johns Hopkins University |
Methodes et compositions pour le traitement de la schizophrenie
|
CN103896787A
(zh)
*
|
2012-12-26 |
2014-07-02 |
江苏康倍得药业有限公司 |
一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
|
WO2014111790A2
(fr)
|
2013-01-15 |
2014-07-24 |
Zydus Technologies Limited |
Système d'administration de médicament pharmaceutique transdermique stable comprenant de la rivastigmine
|
WO2014144663A1
(fr)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Procédés et compositions pour améliorer la fonction cognitive
|
EP2968220B1
(fr)
|
2013-03-15 |
2021-05-05 |
Agenebio, Inc. |
Procédés et compositions pour améliorer la fonction cognitive
|
CN103319374B
(zh)
*
|
2013-06-09 |
2015-04-22 |
无锡佰翱得生物科学有限公司 |
一种(s)-卡巴拉汀的不对称合成方法
|
WO2015022418A1
(fr)
|
2013-08-16 |
2015-02-19 |
Takeda Gmbh |
Traitement d'une déficience cognitive à l'aide d'un inhibiteur de pde4
|
WO2015095783A1
(fr)
|
2013-12-20 |
2015-06-25 |
Agenebio, Inc. |
Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
|
CN107810002B
(zh)
|
2015-05-22 |
2021-01-05 |
艾吉因生物股份有限公司 |
左乙拉西坦的延时释放药物组合物
|
JP6987384B2
(ja)
|
2015-06-19 |
2021-12-22 |
エージンバイオ, インコーポレイテッド |
ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
|
US20180170941A1
(en)
|
2016-12-19 |
2018-06-21 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
US11505555B2
(en)
|
2016-12-19 |
2022-11-22 |
Agenebio, Inc. |
Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
|
BR112020026062B1
(pt)
|
2018-06-19 |
2023-04-04 |
Agenebio, Inc |
Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
|
KR20200035359A
(ko)
|
2018-09-26 |
2020-04-03 |
캐딜라 파마슈티클즈 리미티드 |
리바스티그민 제조용 중간체의 합성
|
WO2024039886A1
(fr)
|
2022-08-19 |
2024-02-22 |
Agenebio, Inc. |
Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
|